來源:[1] 賽諾菲(ENXTPA:SAN)在突破性罕見疾病療法獲FDA批准後的估值展望 (https://finance.yahoo.com/news/look-sanofi-en ...)[2] 賽諾菲Wayrilz:罕見血液疾病BTK抑制劑市場的戰略突破 - AInvest (https://vertexaisearch.cloud.google.com/groun ...)[3] 賽諾菲Wayrilz:罕見疾病和免疫學市場的顛覆者 - AInvest (https://ainvest.com/sanofis-wayrilz-a-game-ch ...)